Any type of interferon reasonable? for any stage of COVID?

I actually think that is why plaquenil works. The porphyrin stuff on RBCs

Marcus Aurelius said:

---

Witnessing another one. Symptom day 10 sudden huge spike in ferritin, CRP, LFTs and neutrophil/lymphocyte ratio. Chest x-ray ARDS exploding. Max vent, proned. New onset renal failure and shock. Depressing. Nothing to do but watch the inevitable play out. Steroids? Can't get compassionate IL-6 inhibitors now.

---

Actemra(tocilizumab) is unavailable in your hospital??

correct

Gents - a non medical professional likely asking a dumb question - but will blood doping, EPO, other oxygen enhancing mixtures be effective here when IL-6 inhibitors (tocilizumab) aren't available?

Quote:

---

Outside of select centers, you pretty much have to enroll the patient in a clinical trial in order to get them right now.

---

Infection_Ag or Marcus, Are y'all participating in any COVID studies? There are a ton ongoing or just about to start up, many focusing on the inflammation aspect in these severe cases.

We are looking into it. Sure you saw the FDA phase III trial approval recently.

Kevzara is also getting the same compassionate use as Actemra isn't it?

NawlinsAg01 said:

---

Quote:

---

Outside of select centers, you pretty much have to enroll the patient in a clinical trial in order to get them right now.

---

Infection_Ag or Marcus, Are y'all participating in any COVID studies? There are a ton ongoing or just about to start up, many focusing on the inflammation aspect in these severe cases.

---

Yes, sarilumab and remdesivir. We have toci in limited quantities.

Today was Humanigen right? There's a ton of earlier phase stuff coming through as well. Hoping some of it pans out.

Marcus Aurelius said:

---

Talked to our head pharm-D. She is calling the appropriate people tonight. She will request a compassionate usage order. THX again.

---

Dm'd you

Double post Dm'd you

Leronlimab

CytoDyn, developer of leronlimab announced in a press release that after 3 days of treatment with leronlimab, 8 patients with COVID-19 who are seriously ill have shown an improvement in several important immunologic biomarkers, including cytokines, interleukin (IL)-6, and a trend toward the normalization of the CD4/CD8 ratio.5

"We are very pleased with our most recent laboratory data for patients treated with leronlimab for COVID-19 infection. We continue to see increases in the profoundly decreased CD8 T-lymphocyte percentages by Day 3, normalization of CD4/CD8 ratios, and resolving cytokine production including reduced IL-6 correlating with patient improvement. The current data suggests a trend toward the restoration of immune function and mitigation of the cytokine storm. This is consistent with prior laboratory results in the first four patients treated for COVID-19 with leronlimab," Bruce Patterson, MD, CEO and founder of IncellDx, a partner of CytoDyn's, said in a statement.5

The randomized, double-blind, placebo-controlled phase II study of leronlimab as treatment of COVID-19 is expected to include 75 patients from up to 10 treatment centers in the United States. CytoDyn has also filed for the initiation of a phase II/III trial for the treatment of severely ill patients with COVID-19. This double-blind trial is expected to enroll 342 patients and randomize them in a 2:1 ratio. The primary end point of this trial is the mortality rate at 14 days.6

robdobyns said:

---

The press release was published online by Targeted Oncology tonight at 8 PM.
This experimental drug might be available. It's a very small biotech company so they should be quick on their feet.

---

Excellent. THX.

Has anyone used or considered the JAK inhibitors? They haven't gotten as much coverage but there's early literature and COVID trials starting. I makes sense if IL6 is as critical as we think since the JAK path is kicked off by IL6. If other cytokines are also problematic inhibiting JAK would prevent their actions as well.

Also, the reported WBC abnormalities are very interesting. Almost like a type of leukemia. There might be room there for other treatments.

Phase 3 Trial

Maybe some help on the way...

Jbiv230987 said:

---

Just passing along as some additional thinking on the possible cause...


https://t.co/XuqjcziRLY?amp=1

---

This is really interesting. Thanks for sharing.

The links in the three posts above mine are very good reads for an average shlub like me. Thank y'all so much for posting.

So let's say the particular medication discussed in the first release turns out to be truly effective...how long does it realistically take to get those meds distributed and into the hands of doctors treating relevant patients?

Yes JAK inhibitors should definitely be under consideration. Saw Novartis was starting a trial.

Here is a preprint this morning I found looking at the virus-host interatome and they suggest that viral nonstructure proteins are interacting with an NF-kB repressor that leads to high IL6/IL8 levels and neutrophil migration to the lungs. They suggest IL6, IL8 and JAK1 and JAK3 inhibitors

kyledr04 said:

---

Has anyone used or considered the JAK inhibitors? They haven't gotten as much coverage but there's early literature and COVID trials starting. I makes sense if IL6 is as critical as we think since the JAK path is kicked off by IL6. If other cytokines are also problematic inhibiting JAK would prevent their actions as well.

Also, the reported WBC abnormalities are very interesting. Almost like a type of leukemia. There might be room there for other treatments.

---

Some great ideas. Thanks.

Jbiv230987 said:

---

Just passing along as some additional thinking on the possible cause...


https://t.co/XuqjcziRLY?amp=1

---

This article references Avigan as a possible treatment. Do we have wide access to Avigan in the US?